Why the study?
Adverse left-ventricular remodelling after acute myocardial infarction causes cardiac dysfunction and worsens prognosis, prompting evaluation of peripheral blood mRNA transcripts to identify patients who develop remodelling.
Does versican mRNA transcript expression predict adverse left-ventricular remodelling at 6 months in patients with first STEMI treated with PCI?
Does versican mRNA transcript expression predict adverse left-ventricular remodelling at 6 months in patients with first STEMI treated with PCI?
Decreased expression of versican (VCAN) mRNA in the acute phase of STEMI is an independent predictor of adverse left-ventricular remodelling at 6 months.
BACKGROUND: Adverse left-ventricular remodelling (LVR) is defined as an increase in end-diastolic left-ventricular volume by 20% 6 months after acute myocardial infarction (AMI). LVR is associated with cardiac dysfunction, therefore deteriorating the prognosis. AIMS: We aimed to compare the concentrations of messenger RNA transcripts in the peripheral blood of patients with and without LVR at 6 months. METHODS: The study included 75 patients with first ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention. Whole blood concentrations of 6 transcripts were determined 24 hours after AMI using droplet digital polymerase chain reaction. The correlations between mRNA transcript expression and left ventricular ejection fraction (LVEF) and N-terminal-pro B type natriuretic peptide (NT-proBNP) concentration were evaluated. RESULTS: Among 75 patients, 4 were lost to follow-up and 71 were included in the analysis. Seventeen (24%) patients developed LVR at 6 months. Versican (VCAN) mRNA expression was lower in patients who developed LVR, compared to those who did not (P = 0.02), and discriminated between these patients (area under the ROC curve 67%; P = 0.04). Expression of VCAN transcript < 75.3 normalized units predicted LVR with 71% sensitivity and 67% specificity. In a multivariable regression analysis, VCAN expression remained the only independent predictor of LVR (OR 3.475; 95% CI, 1.000-12.075; P = 0.04). CONCLUSIONS: Dysregulation of VCAN expression in the acute phase of AMI may contribute to LVR at 6 months. Whether decreased expression of VCAN might be a useful tool to predict LVR in clinical practice remains to be established.
No takes yet. Share an insight, caveat, or question.
Chabior et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: